Research libraryBiblioteka istraživanja

Beyond
“studies show.”Dalje od
„studije pokazuju“.

Structured evidence dossiers show what was studied, in whom, for how long, against what comparator—and what the result cannot establish.Strukturirani dosijei dokaza prikazuju šta je proučavano, kod koga, koliko dugo, prema kom komparatoru—i šta rezultat ne može da utvrdi.

01

Read the primary sourcePročitaj primarni izvor

02

Separate human from preclinicalOdvoji ljudsko od pretkliničkog

03

Record funding and limitsZabeleži finansiranje i granice

Reviewed 7 September 2026Pregledano 7. septembar 2026.

Structured dossiersStrukturirani dosijei

One study.
All the context.Jedna studija.
Sav kontekst.

The launch set begins with pivotal retatrutide trials. Additional dossiers are added only after the same fields have been checked against the primary paper or registry.Početni skup počinje ključnim studijama retatrutida. Dodatni dosijei se dodaju tek nakon provere istih polja prema primarnom radu ili registru.

RL-001 · Retatrutide

TRANSCEND-T2D-1: retatrutide monotherapy in type 2 diabetesTRANSCEND-T2D-1: monoterapija retatrutidom kod dijabetesa tipa 2

Phase IIIFaza III
DesignDizajn
Randomized, double-blind, placebo-controlled, parallel-group trialRandomizovana, dvostruko slepa, placebom kontrolisana studija paralelnih grupa
SampleUzorak
537 adults537 odraslih
ExposureIzloženost
Once weekly; 4 mg, 9 mg or 12 mg target doseJednom nedeljno; ciljna doza 4 mg, 9 mg ili 12 mg
DurationTrajanje
40-week primary endpointPrimarni ishod u 40. nedelji
EndpointIshod
Change in HbA1c; body weight and safety as additional outcomesPromena HbA1c; telesna masa i bezbednost kao dodatni ishodi
ComparatorKomparator
PlaceboPlacebo
FundingFinansiranje
Eli Lilly and CompanyEli Lilly and Company
What it showedŠta je pokazala

In this defined population, the trial reported improvements in glycaemic control and body weight across active groups.U ovoj definisanoj populaciji, studija je prijavila poboljšanja glikemijske kontrole i telesne mase u aktivnim grupama.

What it did not showŠta nije pokazala

It did not establish rare or very long-term harms, cardiovascular benefit, performance against an active comparator, or suitability outside the protocol.Nije utvrdila retke ili veoma dugoročne štete, kardiovaskularnu korist, učinak prema aktivnom komparatoru niti pogodnost van protokola.

Major limitations:Glavna ograničenja: Sponsor-funded; 40-week primary endpoint; selected population using diet and exercise without other glucose-lowering therapy.Finansirao sponzor; primarni ishod u 40. nedelji; odabrana populacija na režimu ishrane i fizičke aktivnosti bez druge terapije za snižavanje glukoze.

Open primary recordOtvori primarni zapis
RL-002 · Retatrutide

Triple-hormone-receptor agonist retatrutide for obesityRetatrutid, agonista tri hormonska receptora, za gojaznost

Phase IIFaza II
DesignDizajn
Randomized, double-blind, placebo-controlled dose-ranging trialRandomizovana, dvostruko slepa, placebom kontrolisana studija raspona doza
SampleUzorak
338 adults without type 2 diabetes338 odraslih bez dijabetesa tipa 2
ExposureIzloženost
Once weekly; 1 mg to 12 mg dose groupsJednom nedeljno; grupe od 1 mg do 12 mg
DurationTrajanje
48 weeks; primary endpoint at week 2448 nedelja; primarni ishod u 24. nedelji
EndpointIshod
Percentage change in body weightProcentualna promena telesne mase
ComparatorKomparator
PlaceboPlacebo
FundingFinansiranje
Eli Lilly and CompanyEli Lilly and Company
What it showedŠta je pokazala

The study reported dose-dependent body-weight reductions over 48 weeks, with gastrointestinal events the most common adverse events.Studija je prijavila smanjenje telesne mase zavisno od doze tokom 48 nedelja, uz gastrointestinalne događaje kao najčešće neželjene događaje.

What it did not showŠta nije pokazala

It did not establish regulatory approval, long-term outcomes, rare harms, or equivalence to any non-trial material.Nije utvrdila regulatorno odobrenje, dugoročne ishode, retke štete niti ekvivalentnost bilo kom materijalu van studije.

Major limitations:Glavna ograničenja: Phase II size and duration; no active comparator; sponsor-funded development trial.Veličina i trajanje faze II; bez aktivnog komparatora; razvojnu studiju finansirao sponzor.

Open primary recordOtvori primarni zapis
RL-003 · Retatrutide

Retatrutide in people with type 2 diabetesRetatrutid kod osoba sa dijabetesom tipa 2

Phase IIFaza II
DesignDizajn
Randomized, double-blind, double-dummy, placebo- and active-controlled trialRandomizovana, dvostruko slepa, double-dummy, placebom i aktivno kontrolisana studija
SampleUzorak
281 adults281 odraslih
ExposureIzloženost
Once weekly; 0.5 mg to 12 mg maintenance groupsJednom nedeljno; grupe održavanja od 0,5 mg do 12 mg
DurationTrajanje
36 weeks; primary endpoint at week 2436 nedelja; primarni ishod u 24. nedelji
EndpointIshod
Change in HbA1c; body weight and safety as secondary outcomesPromena HbA1c; telesna masa i bezbednost kao sekundarni ishodi
ComparatorKomparator
Placebo and dulaglutide 1.5 mgPlacebo i dulaglutid 1,5 mg
FundingFinansiranje
Eli Lilly and CompanyEli Lilly and Company
What it showedŠta je pokazala

The trial reported dose-related glycaemic and body-weight changes; gastrointestinal adverse events were common in retatrutide groups.Studija je prijavila promene glikemije i telesne mase povezane sa dozom; gastrointestinalni neželjeni događaji bili su česti u grupama sa retatrutidom.

What it did not showŠta nije pokazala

It did not determine long-term clinical outcomes, use in broader populations, or the quality of unrelated material.Nije utvrdila dugoročne kliničke ishode, primenu u širim populacijama niti kvalitet nepovezanog materijala.

Major limitations:Glavna ograničenja: 36-week Phase II trial; attrition; multiple dose groups; sponsor-funded, with company-employed authors.Studija faze II od 36 nedelja; osipanje učesnika; više grupa doza; finansirao sponzor, uz autore zaposlene u kompaniji.

Open primary recordOtvori primarni zapis

Compound research indexIndeks istraživanja jedinjenja

Evidence by
compound.Dokazi po
jedinjenju.

Compound profiles connect mechanism, human evidence, preclinical evidence, safety boundaries, regulatory status and live literature searches.Profili jedinjenja povezuju mehanizam, ljudske dokaze, pretkliničke dokaze, bezbednosne granice, regulatorni status i aktuelne pretrage literature.

Published phase II and III evidenceObjavljeni dokazi faze II i IIIRetatrutideRetatrutidEarly human researchRana istraživanja na ljudimaAOD-9604AOD-9604Components studied separatelyKomponente proučavane odvojenoCJC-1295 / IpamorelinCJC-1295 / IpamorelinFormulation must be definedFormulacija mora biti definisanaKLOWKLOWFormulation must be definedFormulacija mora biti definisanaGLOWGLOWVariable blend · mostly preclinicalPromenljiva mešavina · uglavnom pretkliničkiWolverine StackWolverine StackPreclinical and cell researchPretklinička i ćelijska istraživanjaEpitalon (Epithalon)Epitalon (Epithalon)FDA-approved product · narrow indicationFDA odobren proizvod · uska indikacijaSS-31 (Elamipretide)SS-31 (Elamipretid)Preclinical + observational human biologyPretklinički + opservaciona biologija kod ljudiMOTS-cMOTS-cNot a peptide · limited direct human evidenceNije peptid · ograničeni direktni dokazi kod ljudiNAD+NAD+